National Central Pharmacy (Abilene Nuclear LLC), Abilene, TX

Is National Central Pharmacy (Abilene Nuclear LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Ceased Compounding Operations”.

Does National Central Pharmacy (Abilene Nuclear LLC) hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed.

Has National Central Pharmacy (Abilene Nuclear LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Oct 22, 2020) and 1 FMD-145 letter (Jan 25, 2022) for National Central Pharmacy (Abilene Nuclear LLC). Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Abilene Nuclear LLC; National Central Pharmacy
Location
Abilene, TX
Type as FDA labels it
503A
FDA’s note
Ceased Compounding Operations
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jan 25, 2022
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 8 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Abilene Nuclear LLC, (dba National Central Pharmacy), a 503A facility, with 3 dated actions.

Document
Jan 25, 2022FMD-145 letterFMD-145 Letter Issued 01/25/2022Not linked by FDA
Oct 22, 2020Untitled letterUntitled Letter Issued 10/22/2020fda.gov
Nov 7, 2019Form 483483 Issued 11/07/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Abilene Nuclear LLC, Abilene, TX (FEI number 3004819860), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Nov 7, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30048198601109230

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Oct 28, 2019 to Nov 7, 2019: 8 observations

Firm on the cover
Abilene Nuclear LLC dba National Central Pharmacy, 3402 s 14th St, Abilene, TX 79605-4904
FEI number
3004819860
Establishment type on the cover
Manufacturer
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Personnel engaging in aseptic processing was observed with exposed skin.

Specifically, your firm's pharmacy manager was observed during the production the non-patient specific sterile drug product, EPI-Shugarcaine Su/F Ophth 1 ml/vial, Rx <Redacted B4> as having his head, partially exposed facial skin, inside LAF Hood <Redacted B4>

Observation 2

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically, your pharmacy manager failed to adequately disinfect materials transferred from the ISO 7 Cleanroom into LAF Hood <Redacted B4> which was later used in the production of sterile drug products. For example, on 10/30/2019, I observed your pharmacy manager aseptically process the drug product for "Office Use Only", EPI-Shugarcaine Su/F Ophth 1 ml/vial, Rx <Redacted B4> 1-ml vials, Expi1y 11/13/2019. While producing this lot of sterile drug product, I observed the following items were not disinfected prior to entering the ISO 5 LAF Hood <Redacted B4>

A. During setup for production, your pharmacy's manager failed to disinfect the tray containing ampules of Lidocaine 4% Pres-Free prior to entering the ISO 5 LAF hood. The ampules were removed from the non-disinfected tray and disinfected once inside the LAF hood.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Personnel touched equipment or other surfaces located outside of the ISO 5 classified aseptic processing area with gloved hands and then engaged in aseptic processing without changing or sanitizing gloves.

Specifically, your firm pharmacy failed to disinfect sterile gloves prior to re-entry into ISO 5 LAF hood while aseptically processing the sterile drug product, EPI-Shugarcaine Su/F Ophth 1 ml/vial after collecting additional supplies in the ISO 7 Cleanroom too many times to count. At the completion of aseptic processing, I observed your firm's pharmacy manager pick paper off the floor, place it into the trashcan, and return into the ISO 5 LAF hood without disinfecting and or change the sterile gloves prior to re-entry into the ISO 5 area.

Observation 4

Personnel placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically, your firm's pharmacy manager failed to place supplies in an area, which would not inhibit first pass airflow within LAF Hood <Redacted B4> during aseptic processing. For example, during the aseptic processing of the sterile drug product, EPI-Shugarcaine Su/F Ophth 1 ml/vial, Rx <Redacted B4> I observed empty/filled vials and Lidocaine 4% Pres-Free 4.5 mis ampules ananged in a manner that created a disruption in first pass airflow within the ISO 5 LAF hood.

Observation 5

The facility design was observed to allow the influx of poor quality air into a higher classified area.

Specifically, your firm failed to have adequate HEP A filter coverage in the prevention of poor quality air from entering into your ISO 7 Cleanroom, high quality air area. For example, your firm's cleanroom is designed with <Redacted B4> your firm's ISO 7 Cleanroom and non-classified radio-pharmaceutical inspection/ packaging/ shipping/ receiving/ cleaning area, which fails to have adequate HEP A filter coverage to ensure poor air quality does not enter into the ISO 7 Cleanroom. Additionally, your fnm failed to include the <Redacted B4> as part of your firm's cleanroom <Redacted B4> recertification to verify air quality.

air from entering fto yo,· ISO 7 CleanroomJ!igll_gualitv air area. For example, your fnm's cleanroom is designed with (15) (4) Ko) (~) lyour fnm's ISO 7 Cleanroom and non- classified radio-phrumaceutical inspection/ packaging/ shipping/ receiving/ cleaning area, which fails to have adequate HEP A filter coverage to ensure poor air qualicy does not enter into the ISO 7 Cleanroom. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Disinfecting agents and cleaning pads or wipes used in the ISO 5 aseptic processing are not sterile.

Specifically, your firm is using the non-sterile cleaning product, <Redacted B4> within your firm's LAF Hood <Redacted B4> designated for the production of sterile drug product.

Observation 7

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worse-case activities and conditions that provide a challenge to aseptic operations.

Specifically, your firm procedure, Media Fill Challenge, Document # 6.36, Change# 2, documents the use of a <Redacted B4> Your firm's PIC reported the manipulations and complexity performed using the kit is representative of those performed during radio-pharmaceutical drug processing. The same kit components were modified to simulates non-radio-pharmaceutical aseptic transfers that uses a <Redacted B4> manipulation into syringes. The simulated media fill fail to be representative of your firm's non-radio-pharma aseptic processing worse-case activities and conditionst.

Observation 8

The batch production and control records are deficient in that they do not include identification of persons performing and checking each significant step in the operation.

Specifically, your firm's production worksheets failed to include a second verifier for critical steps of your pharmacy's production process. For example, during my review of the following selected production batch records, I found only your firm's pharmacist, who produced the drug product, was the only firm employee who reviewed and approved the production batch/lot. Your pharmacy failed to have a second person to verify defined critical steps within the production process that effect finished drug product identity, strength, quality, and purity.

A. Rx <Redacted B4> , Cefuroxime 7.5mg/ml Ophth Soln 2.5 mls, Expiry 1/18/2019

B. Rx <Redacted B4> EPI-Shugai·caine Su/F Ophth 1 ml/vial, Expiry 11/13/2019

C. Rx <Redacted B4> , Joint Mix Ropiv/Morph 10 mg, Expi1y 10/10/2019

D. Rx <Redacted B4> Joint Mix# 2 Bupiv/Morph, Expi1y 9/11/2019

1 E. RX <Redacted B4> , HAB 1-0.5-25 per 0.2 ml Lipo, Expi1y 1/21/2020

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.